3.49
+0.87%
Close of 9 Nov 2026, in PLN
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Bioton
Its shares trade on GPW under the ticker BIO.WA. It has been listed since 16 March 2005. In the fiscal year to 31 December 2025, it reported revenue of PLN 282.5m and net income of PLN 3.4m. At that date it held total assets of PLN 764.6m and shareholders' equity of PLN 594.0m.
BIOTON SA engages in the manufacture and production of medicine and pharmaceutical substances. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2005-03-16. The firm is engaged in research, development and wholesale trade of pharmaceutical and biotechnological products. The firm's portfolio consists of oral hypoglycemic drugs (metformin and glimepride) as well as recombinant human insulin in pharmaceutical substance form and for injections. Additionally, the Company provides advertising services. As of December 31, 2011, the Company formed a capital group and operated through its subsidiaries, including BIOTON TRADE Sp. z o.o., Mindar Holdings Ltd, Germonta Holdings Ltd, Tricel SA, SciGen Ltd and BioPartners Holdings AG, among others. On June 12, 2014, it sold a 50% stake in Copernicus Sp. z o.o.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 16 Mar 2005
- Employees
- 527
- Website
- bioton.pl ↗
Leadership
Pay as last reported
- Mr. Nicola CadeiChairman of the Supervisory Board, since 2019PLN 39,000
- Mr. Jeremy LaundersChairman of the Management Board, Chief Executive OfficerPLN 1.8m
- Mr. Ramesh RajentheranVice Chairman of the Supervisory Board, since 2019PLN 36,000
- Mr. Dariusz TrzeciakVice President of the Supervisory Board, since 2013PLN 36,000
- Mr. Romuald HarwasMember of the Management Board
- Dr. Jubo LiuMember of the Supervisory Board, since 2016PLN 24,000
- Mr. Tomasz SiembidaMember of the Supervisory Board, since 2017PLN 12,000
- Mr. Vaidyanathan ViswanathMember of the Supervisory Board, since 2016PLN 24,000
- Mr. Khee Wee HauMember of the Supervisory BoardPLN 12,000
- Mr. Kaiguo XiaMember of the Supervisory Board
- Ms. Katarzyna StalinskaManagement Board Office Coordinator, since 2018
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Bioton SA has a strong market presence and brand recognition in the pharmaceutical industry. The company's extensive experience and expertise in the development and manufacturing of biotechnology and pharmaceutical products give it a competitive advantage. Additionally, Bioton SA has a diverse product portfolio, catering to various medical needs.
Weaknesses
- One weakness of Bioton SA is its dependence on a limited number of key products. This exposes the company to market fluctuations and risks associated with product failures. Bioton SA may also face challenges in terms of intellectual property protection and maintaining a reliable supply chain.
Opportunities
- There are several opportunities for Bioton SA to explore. The increasing global demand for biotechnology and pharmaceutical products presents a growth opportunity for the company. Bioton SA could also consider expanding its product offerings or entering new markets to diversify its revenue streams. Collaborations and partnerships with other industry players could further enhance Bioton SA's market position.
Threats
- Bioton SA faces threats from intense competition in the pharmaceutical industry. The presence of both established multinational companies and emerging biotech firms can pose challenges to Bioton SA's market share. Additionally, regulatory changes and stringent compliance requirements may impact the company's operations and product development processes. Economic uncertainties and geopolitical factors can also influence Bioton SA's business environment.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.